Aquinox Pharmaceuticals (Canada) Inc.

Quick facts

Phase 2 pipeline

• AQX-1125 · Rheumatology
  AQX-1125 is a small molecule that inhibits the NLRP3 inflammasome.

Phase 1 pipeline

• [14C]-AQX-1125 IV
• [14C]-AQX-1125 Oral Solution

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aquinox Pharmaceuticals (Canada) Inc. portfolio CI brief
• Aquinox Pharmaceuticals (Canada) Inc. pipeline updates RSS